SCHEMBL30730643

SCHEMBL30730643

Cc1nonc1CC(=O)N1CCC(O)(c2nc(-c3ccc(Cl)c(Cl)c3)no2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.42
LMNA P02545 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.41
ALDH1A1 P00352 4/20 0.41
SMO Q99835 1/20 0.39
KIT P10721 2/20 0.37
GFER P55789 1/20 0.36
CNR1 P21554 1/20 0.36
POLB P06746 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
NPC1 O15118 3/20 0.35
HPGD P15428 3/20 0.35
HDAC4 P56524 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730632 0.86 LMNA (0.45) RAB9ALMNAKMT2AMEN1PKM
SCHEMBL30730541 0.82 LMNA (0.41) RAB9ALMNAKMT2AMEN1PKM
SCHEMBL32676619 0.82 MAPT (0.49) LMNAPKMALDH1A1GFERPOLB
SCHEMBL32676704 0.81 LMNA (0.52) LMNAPKMALDH1A1POLBSMN1; SMN2
SCHEMBL30730515 0.77 LMNA (0.45) RAB9ALMNAKMT2AMEN1PKM
SCHEMBL30730664 0.76 PKM (0.42) PKMALDH1A1GFERSMN1; SMN2
SCHEMBL32677165 0.74 LMNA (0.43) RAB9ALMNAKMT2AMEN1PKM
SCHEMBL30730535 0.73 TSHR (0.54) LMNAKMT2AMEN1ALDH1A1POLB
SCHEMBL32676589 0.72 PKM (0.42) RAB9ALMNAKMT2AMEN1PKM
SCHEMBL32676698 0.71 LMNA (0.50) LMNASMN1; SMN2TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 RAB9A 544/4885LMNA 1838/4885KMT2A 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.